Intensity Therapeutics, Inc. (INTS)

NASDAQ: INTS · Real-Time Price · USD
0.4752
+0.0862 (22.16%)
At close: May 30, 2025, 4:00 PM
0.4351
-0.0401 (-8.44%)
After-hours: May 30, 2025, 7:57 PM EDT
22.16%
Market Cap 7.21M
Revenue (ttm) n/a
Net Income (ttm) -15.01M
Shares Out 15.18M
EPS (ttm) -1.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 6,205,490
Open 0.3745
Previous Close 0.3890
Day's Range 0.3629 - 0.5274
52-Week Range 0.2900 - 5.1000
Beta n/a
Analysts Strong Buy
Price Target 8.50 (+1,688.72%)
Earnings Date May 13, 2025

About INTS

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 30, 2023
Employees 7
Stock Exchange NASDAQ
Ticker Symbol INTS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for INTS stock is "Strong Buy." The 12-month stock price forecast is $8.5, which is an increase of 1,688.72% from the latest price.

Price Target
$8.5
(1,688.72% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

SHELTON, Conn. , May 29, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and devel...

2 days ago - PRNewsWire

Intensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the Horizon

SHELTON, Conn. , May 28, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), ("Intensity" or "the Company") a late-stage clinical biotechnology company focused on the discovery and devel...

3 days ago - PRNewsWire

Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Eight Swiss sites are activated in the INVINCIBLE-4 Study, and several patients have been treated European Medicines Agency Authorization to initiate INVINCIBLE-4-Study in France SHELTON, Conn. , May ...

18 days ago - PRNewsWire

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in France

INVINCIBLE-4 (SAKK/66/22) Study continues to recruit patients in eight sites in Switzerland SHELTON, Conn. and BERN, Switzerland , May 6, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INT...

25 days ago - PRNewsWire

Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering

SHELTON, Conn. , April 25, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (NASDAQ: INTS), ("Intensity" or the "Company") a late-stage clinical biotechnology company focused on the discovery and dev...

5 weeks ago - PRNewsWire

Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update

32 sites are currently contracted in the INVINCIBLE-3 Study, and 25 patients have been screened Eight Swiss sites are activated in the INVINCIBLE-4 Study, and several patients have been screened Final...

2 months ago - PRNewsWire

Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review

INVINCIBLE-3 Study continues to recruit patients with leiomyosarcoma, liposarcoma and undifferentiated pleomorphic sarcoma; authorizations for the INVINCIBLE-3 Study have been received in the U.S., Ca...

4 months ago - PRNewsWire

Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6

The US FDA, Health Canada, European Medicines Authority, and the Australian Therapeutic Goods Administration authorized the Company's global, randomized Phase 3 study (INVINCIBLE-3) in Metastatic Soft...

5 months ago - PRNewsWire

Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement

SHELTON, Conn. , Nov. 21, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), ("Intensity" or the "Company") a late-stage clinical biotechnology company focused on the discovery and deve...

6 months ago - PRNewsWire

Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)

Phase 1/2 data showed a median overall survival ("mOS") of 21.3 months versus a synthetic control of 6.7 months, an increase in T-cell activation, and favorable safety profile for patients receiving I...

6 months ago - PRNewsWire

Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

First patient dosed in randomized, Phase 2 study in presurgical triple negative breast cancer SHELTON, Conn. , Nov. 13, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company")...

7 months ago - PRNewsWire

Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting

SHELTON, Conn. , Nov. 8, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), ("Intensity" or "the Company") a late-stage clinical biotechnology company focused on the discovery and devel...

7 months ago - PRNewsWire

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)

Testing the efficacy and safety of Intensity's lead drug candidate, INT230-6, when combined with Standard-of-Care versus Standard-of-Care alone The endpoint is the change in pathological complete resp...

7 months ago - PRNewsWire

Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

SHELTON, Conn., Sept. 4, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel im...

9 months ago - PRNewsWire

Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

First patient dosed in global randomized, Phase 3 study in metastatic soft tissue sarcoma Collaboration agreement with The Swiss Group for Clinical Cancer Research SAKK ("SAKK") to conduct a Phase 2 r...

10 months ago - PRNewsWire

Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma

Testing the efficacy and safety of our lead product candidate, INT230-6, as Monotherapy Compared with Systemic U.S. Standard-of-Care Chemotherapy SHELTON, Conn. , July 9, 2024 /PRNewswire/ -- Intensit...

11 months ago - PRNewsWire

Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors

SHELTON, Conn. , May 15, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and devel...

1 year ago - PRNewsWire

Intensity Therapeutics: A Bargain For A Late-Stage Company With A Remarkable Oncology Drug

Mid-2024, Intensity Therapeutics will start Phase 3 and Phase 2/3 trials  respectively in soft tissue sarcoma and triple-negative breast cancer. INT230-6 has shown up to 95% tumor necrosis, prolonged ...

1 year ago - Seeking Alpha

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate

SHELTON, Conn. , May 10, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and devel...

1 year ago - PRNewsWire

Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

INT230-6, Intensity's lead drug candidate, continues to advance into late-stage clinical programs in sarcoma and breast cancer Cash and investments of $10.5 million expected to fund operations through...

1 year ago - PRNewsWire

Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024

SHELTON, Conn. , April 2, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel i...

1 year ago - PRNewsWire

Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update

INT230-6, Intensity's lead drug candidate, advances into late-stage clinical programs in sarcoma and breast cancer Year-end cash and investments of $14.8 million expected to fund operations through th...

1 year ago - PRNewsWire

Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024

SHELTON, Conn. , March 14, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel ...

1 year ago - PRNewsWire

Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference

SHELTON, Conn. , Feb. 21, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel i...

1 year ago - PRNewsWire